PMID- 37766118
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230930
IS  - 2076-393X (Print)
IS  - 2076-393X (Electronic)
IS  - 2076-393X (Linking)
VI  - 11
IP  - 9
DP  - 2023 Aug 31
TI  - Safety of Interchanging the Live Attenuated MAV/06 Strain and OKA Strain 
      Varicella Vaccines in Children.
LID - 10.3390/vaccines11091442 [doi]
LID - 1442
AB  - Two live attenuated varicella vaccine (VZV) strains have been mainly used across 
      the globe: MAV/06 and OKA strains. We aimed to explore the safety of 
      interchanging the two VZV strains for primary and booster immunizations. South 
      Korea's vaccine adverse event reporting system (VAERS) was accessed and searched 
      to find filed reports of all adverse events (AEs) following immunization with the 
      second dose of the varicella vaccine. The electronic medical records were 
      reviewed for all visits to the hospital following the second dose of the 
      varicella vaccine. Of the total 406 study participants, 27.5% (n = 112) were in 
      the MAV/06-MAV/06 group, 30.3% (n = 123) in the MAV/06-OKA, 17.5% (n = 71) in the 
      OKA-MAV/06 group, and 24.6% (n = 100) in the OKA-OKA group. Mean age at 
      immunization with the first dose was 1.10 (standard deviation [SD] +/-0.34) years 
      old, and second dose was 4.77 (SD +/- 1.13) (p = 0.772 and 0.933, respectively). 
      There were no filed reports of AEs following the second dose in the national 
      VAERS. Hospital visit records showed a total of 10.3% (95% confidence interval 
      [CI], 7.6-13.7) (n = 42) had recorded AEs following the 2nd administered dose; 
      however, only 0.7% (95% CI, 0.2-2.4) (n = 3) were regarded as possibly vaccine 
      related. Two patients in the MAV/06-OKA group were diagnosed with 
      Henoch-Schonlein purpura after the second dose; however, both had also received 
      the MMR vaccine on the same day. No safety signals associated with interchanging 
      the MAV/06 and OKA strain live attenuated varicella vaccines were observed in 
      this patient cohort of healthy children.
FAU - Kang, Hyun Mi
AU  - Kang HM
AUID- ORCID: 0000-0003-0513-8407
AD  - Department of Pediatrics, Seoul St. Mary's Hospital, College of Medicine, The 
      Catholic University of Korea, Seoul 06591, Republic of Korea.
FAU - Kim, Gwanglok
AU  - Kim G
AD  - Department of Corporate Development, GC Biopharma Corporation, Yongin 16924, 
      Republic of Korea.
FAU - Choe, Young June
AU  - Choe YJ
AD  - Department of Pediatrics, Korea University College of Medicine, Korea University 
      Anam Hospital, Seoul 02841, Republic of Korea.
LA  - eng
PT  - Journal Article
DEP - 20230831
PL  - Switzerland
TA  - Vaccines (Basel)
JT  - Vaccines
JID - 101629355
PMC - PMC10536300
OTO - NOTNLM
OT  - MAV/06
OT  - OKA
OT  - safety
OT  - vaccine
OT  - varicella
COIS- The authors declare no conflict of interest. The funders had no role in the 
      collection, analyses, interpretation of data, and writing of the manuscript.
EDAT- 2023/09/28 06:42
MHDA- 2023/09/28 06:43
PMCR- 2023/08/31
CRDT- 2023/09/28 01:44
PHST- 2023/07/28 00:00 [received]
PHST- 2023/08/25 00:00 [revised]
PHST- 2023/08/30 00:00 [accepted]
PHST- 2023/09/28 06:43 [medline]
PHST- 2023/09/28 06:42 [pubmed]
PHST- 2023/09/28 01:44 [entrez]
PHST- 2023/08/31 00:00 [pmc-release]
AID - vaccines11091442 [pii]
AID - vaccines-11-01442 [pii]
AID - 10.3390/vaccines11091442 [doi]
PST - epublish
SO  - Vaccines (Basel). 2023 Aug 31;11(9):1442. doi: 10.3390/vaccines11091442.